1. Time-course analysis of cisplatin induced AKI in preclinical models: implications for testing different sources of MSCs.
- Author
-
Ganguly A, Chetty S, Primavera R, Levitte S, Regmi S, Dulken BW, Sutherland SM, Angeles W, Wang J, and Thakor AS
- Subjects
- Animals, Male, Female, Mice, Inbred C57BL, Time Factors, Chemokine CXCL1 metabolism, Mice, Kidney drug effects, Kidney pathology, Inflammation pathology, Cisplatin adverse effects, Acute Kidney Injury chemically induced, Acute Kidney Injury pathology, Mesenchymal Stem Cells drug effects, Disease Models, Animal
- Abstract
Background: Kidneys are at risk from drug-induced toxicity, with a significant proportion of acute kidney injury (AKI) linked to medications, particularly cisplatin. Existing cytoprotective drugs for cisplatin-AKI carry side effects, prompting a search for better biological therapies. Mesenchymal Stem Cells (MSCs) are under consideration given their regenerative properties, yet their clinical application has not achieved their full potential, mainly due to variability in the source of MSC tested. In addition, translating treatments from rodent models to humans remains challenging due to a lack of standardized dosing and understanding potential differential responses to cisplatin between animal strains., Method: In the current study, we performed a time-course analysis of the effect of cisplatin across different mouse strains and evaluated gender related differences to create a robust preclinical model that could then be used to explore the therapeutic efficacy of different sources of MSCs for their ability to reverse AKI., Result: Our data indicated that different mouse strains produce differential responses to the same cisplatin dosing regimen. Despite this, we did not observe any gender-related bias towards cisplatin nephrotoxicity. Furthermore, our time-course analysis identified that cisplatin-induced inflammation was driven by a strong CXCL1 response, which was used as a putative biomarker to evaluate the comparative therapeutic efficacy of different MSC sources in reversing AKI. Our data indicates that UC-MSCs have a stronger anti-inflammatory effect compared to BM-MSCs and AD-MSCs, which helped to ameliorate cisplatin-AKI., Conclusion: Overall, our data underscores the importance of using an optimized preclinical model of cisplatin-AKI to test different therapies. We identified CXCL1 as a potential biomarker of cisplatin-AKI and identified the superior efficacy of UC-MSCs in mitigating cisplatin-AKI., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF